Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method

Authors

DOI:

https://doi.org/10.14739/2310-1210.2022.4.256945

Keywords:

atrial fibrillation, warfarin, CYP2C9, CYP4F2, VKORC1, genetic polymorphism, pharmacogenetics, excessive hypocoagulation, bleeding

Abstract

The aim. To evaluate the efficacy and safety of warfarin (WF) therapy in patients with atrial fibrillation (AF) using pharmacogenetic dosing method at an anticoagulant monitoring office according to the results of a one-year prospective follow-up.

Materials and methods. The study involved 110 patients with AF (mean age 68.72 ± 0.79; men – 57, women – 53). By the method of stratified randomization, the patients with AF were divided into two groups: the main group – 50 patients with AF and genotype-guided dosing method, the control group – 60 patients with AF and clinical dosing method. The outcomes were examined after the one-year follow-up: excessive hypocoagulation episodes (INR > 4) and bleeding. CYP2C9, CYP4F2, VKORC1 gene polymorphisms were determined using multiplex real time polymerase chain reaction; INR was controlled monthly; CHA2DS2-VASC, HAS-BLED, SAMe-TT2R2 scale scores were evaluated; TTR was calculated using the Rosendaal method.

Results. The distribution of CYP2C9, CYP4F2, VKORC1 genotypes in the main and control groups were in accordance with the Hardy–Weinberg equilibrium. In patients with AF and genotype-guided dosing, the frequency and risk of excessive hypocoagulation episodes (χ2 = 5.11; P < 0.05; RR = 0.50 (CI 0.27; 0.94)) and bleeding (χ2 = 9.57; P < 0.05; RR = 0.41 (CI 0.22; 0.77)) were significantly lower. However, the groups did not differ in TTR.

The validity of genetic-guided dosing was confirmed by the comparability of the medians and the direct correlation between the calculated and therapeutic WF doses (r = +0.57; P < 0.05). There were no relationships between TTR, excessive hypocoagulation episodes, hemorrhagic complications and clinical and genetic factors in the main group.

Conclusions. In patients with AF, the use of genotype-guided dosing method in the anticoagulant monitoring office helped to reduce the frequency and risk of excessive hypocoagulation episodes and bleeding as well as eliminate the influence of endogenous and exogenous factors in the personalized management of patients.

 

Author Biographies

M. Yu. Kolesnyk, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Family Medicine, Therapy, Cardiology and Neurology of Faculty of Postgraduate Education

Ya. M. Mykhailovskyi, Zaporizhzhia State Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Family Medicine, Therapy, Cardiology and Neurology of Faculty of Postgraduate Education

References

Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J. P., Lettino, M., Lip, G., Pinto, F. J., Thomas, G. N., … ESC Scientific Document Group (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal, 42(5), 373-498. https://doi.org/10.1093/eurheartj/ehaa612

Jame, S., & Barnes, G. (2020). Stroke and thromboembolism prevention in atrial fibrillation. Heart, 106(1), 10-17. https://doi.org/10.1136/heartjnl-2019-314898

Gong, I. Y., Schwarz, U. I., Crown, N., Dresser, G. K., Lazo-Langner, A., Zou, G., Roden, D. M., Stein, C. M., Rodger, M., Wells, P. S., Kim, R. B., & Tirona, R. G. (2011). Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PloS one, 6(11), e27808. https://doi.org/10.1371/journal.pone.0027808

Vazquez, S. R. (2018). Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology. American Society of Hematology. Education Program, 2018(1), 339-347. https://doi.org/10.1182/asheducation-2018.1.339

Danese, E., Raimondi, S., Montagnana, M., Tagetti, A., Langaee, T., Borgiani, P., Ciccacci, C., Carcas, A. J., Borobia, A. M., Tong, H. Y., Dávila-Fajardo, C., Rodrigues Botton, M., Bourgeois, S., Deloukas, P., Caldwell, M. D., Burmester, J. K., Berg, R. L., Cavallari, L. H., Drozda, K., Huang, M., … Fava, C. (2019). Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Clinical pharmacology and therapeutics, 105(6), 1477-1491. https://doi.org/10.1002/cpt.1323

Sun, X., Yu, W. Y., Ma, W. L., Huang, L. H., & Yang, G. P. (2016). Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical reports, 4(4), 498-506. https://doi.org/10.3892/br.2016.599

Al-Eitan, L. N., Almasri, A. Y., & Khasawneh, R. H. (2019). Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy. Saudi pharmaceutical journal : SPJ, 27(4), 484-490. https://doi.org/10.1016/j.jsps.2019.01.011

Kolesnyk, M. Y., & Mykhailovskyi, Y. M. (2021). Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region. Zaporizhzhia Medical Journal, 23(4), 476-479. https://doi.org/10.14739/2310-1210.2021.4.227002

Asiimwe, I. G., Zhang, E. J., Osanlou, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Warfarin dosing algorithms: A systematic review. British journal of clinical pharmacology, 87(4), 1717-1729. https://doi.org/10.1111/bcp.14608

Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., Lee, M. T., Gage, B. F., Kimmel, S. E., Perera, M. A., Anderson, J. L., Pirmohamed, M., Klein, T. E., Limdi, N. A., Cavallari, L. H., & Wadelius, M. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clinical pharmacology and therapeutics, 102(3), 397-404. https://doi.org/10.1002/cpt.668

Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., Milligan, P. E., Grice, G., Lenzini, P., Rettie, A. E., Aquilante, C. L., Grosso, L., Marsh, S., Langaee, T., Farnett, L. E., Voora, D., Veenstra, D. L., Glynn, R. J., Barrett, A., & McLeod, H. L. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical pharmacology and therapeutics, 84(3), 326-331. https://doi.org/10.1038/clpt.2008.10

Eljilany, I., Elewa, H., & Al-Badriyeh, D. (2022). Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Current problems in cardiology, 101128. Advance online publication. https://doi.org/10.1016/j.cpcardiol.2022.101128

Zhu, Y., Moriarty, J. P., Swanson, K. M., Takahashi, P. Y., Bielinski, S. J., Weinshilboum, R., Wang, L., & Borah, B. J. (2021). A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?. Genetics in medicine, 23(3), 461-470. https://doi.org/10.1038/s41436-020-00995-w

Moloney, E., Craig, D., Holdsworth, N., & Smithson, J. (2019). Optimising clinical effectiveness and quality along the atrial fibrillation anticoagulation pathway: an economic analysis. BMC health services research, 19(1), 1007. https://doi.org/10.1186/s12913-019-4841-3

Zhang, J., Wu, T., Chen, W., Fu, J., Xia, X., & Chen, L. (2020). Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting. Frontiers in pharmacology, 10, 1527. https://doi.org/10.3389/fphar.2019.01527

Zhang, F., Zhang, C., Gu, C., Yu, Y., & Li, J. (2022). A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement. BMC cardiovascular disorders, 22(1), 183. https://doi.org/10.1186/s12872-022-02620-x

Dahal, K., Sharma, S. P., Fung, E., Lee, J., Moore, J. H., Unterborn, J. N., & Williams, S. M. (2015). Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest, 148(3), 701-710. https://doi.org/10.1378/chest.14-2947

Shi, C., Yan, W., Wang, G., Wang, F., Li, Q., & Lin, N. (2015). Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PloS one, 10(12), e0144511. https://doi.org/10.1371/journal.pone.0144511

Tse, G., Gong, M., Li, G., Wong, S. H., Wu, W., Wong, W. T., Roever, L., Lee, A., Lip, G., Wong, M., Liu, T., & International Health Informatics Study (IHIS) Network (2018). Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. British journal of clinical pharmacology, 84(9), 1868-1882. https://doi.org/10.1111/bcp.13621

Jorgensen, A. L., Prince, C., Fitzgerald, G., Hanson, A., Downing, J., Reynolds, J., Zhang, J. E., Alfirevic, A., & Pirmohamed, M. (2019). Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. BMC medicine, 17(1), 76. https://doi.org/10.1186/s12916-019-1308-7

Heneghan, C., Tyndel, S., Bankhead, C., Wan, Y., Keeling, D., Perera, R., & Ward, A. (2010). Optimal loading dose for the initiation of warfarin: a systematic review. BMC cardiovascular disorders, 10, 18. https://doi.org/10.1186/1471-2261-10-18

Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J., & Briët, E. (1993). A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and haemostasis, 69(3), 236-239.

Apostolakis, S., Sullivan, R. M., Olshansky, B., & Lip, G. (2013). Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest, 144(5), 1555-1563. https://doi.org/10.1378/chest.13-0054

Kolesnyk, M. Y., & Mykhailovskyi, Y. M. (2021). The interrelation of CYP2C9, CYP4F2, VKORC1 genes polymorphisms with warfarin dose and hemorrhagic complications risk rise in patients with atrial fibrillation: a retrospective study. East European science journal, 1(1), 37-43.

Published

2022-09-06

How to Cite

1.
Kolesnyk MY, Mykhailovskyi YM. Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method. Zaporozhye Medical Journal [Internet]. 2022Sep.6 [cited 2024Oct.5];24(4):390-5. Available from: http://zmj.zsmu.edu.ua/article/view/256945

Issue

Section

Original research